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Abstract: The simultaneous measurement of the decrease of available FeII and the 
increase of available FeIII allowed the analysis of the ferroxidase activity of two 
distinct apoferritins. Although recombinant human apoferritin (HuFtH) rapidly 
oxidizes FeII to FeIII, this is not properly stored in the ferritin cavity, as occurs in 
horse spleen H/L-apoferritin (HsFt). Fe storage in these apoferritins was also 
studied in the presence of two Cu-loaded mammalian metallothioneins (MT2 and 
MT3), a scenario occurring in different brain cell types. For HuFtH, unstored FeIII 
triggers the oxidation of Cu-MT2 with concomitant CuI release. In contrast, for HsFt, 
there is no reaction with Cu-MT2. Similarly, Cu-MT3 does not react during either 
HuFtH or HsFt Fe reconstitution. Significantly, the combination of ferritin and 
metallothionein isoforms reported in glia and neuronal cells are precisely those 
that avoid a harmful release of FeII and CuI ions. 
 
Iron is an essential element for organisms but it is highly toxic in excess. It is 
well known that free FeII promotes the formation of highly reactive oxygen 
species capable of causing irreversible cell damage.[1] Organisms have 
developed chemical machinery based on the ferritin family of proteins to 
manage the availability of vital, but potentially toxic, free FeII.[2-4] Thus, every type 
of tissue must contain an appropriate type of ferritin (Ft) that scavenges for and 
stores any Fe which is not required for immediate metabolic purposes. Therefore 
the Fe is rendered non-toxic and yet still available for when it is required by the 
cell. The structures of many Ft proteins isolated from a wide range of organisms 
and biological tissues have been determined. The most extensively studied 
ferritin is that found in horse spleen, traditionally used as a model for 
mammalian Ft. It consists of a hollow protein shell composed of 24 subunits 
arranged in cubic symmetry and has a Mr of about 450 kDa. The shell 





thousands of Fe atoms as an FeIII mineral, often described as ferrihydrite, 
[FeIII10O14(OH)2 ]. [5]  
There are two different types of monomer included in the 24 subunits which 
compose the Ft shell: the heavy (H) subunits, 178 amino acids and 21 kDa, and the 
light (L) subunits, 171 aminoacids and 19 kDa, and each have different 
functionality. Thus, whereas the H monomers play a key role in rapid Fe 
detoxification, because they contain a catalytic ferroxidase center for F e I I  
oxidation, the L subunits seem to be associated with Fe nucleation, 
mineralization and long-term Fe storage in the ferritin cavity.[2] In accordance 
with this, the H/L ratio in a ferritin shell varies widely in different organisms and 
different tissues, but it is worth noting that Ft proteins with a combination of H 
and L subunits are only found in vertebrates. In this subphylum, L-subunit-rich 
ferritins predominate in Fe storage organs such as the liver and spleen, whereas 
organs that require Fe detoxification, such as the heart and most brain cells, 
contain mostly H-rich ferritins. As an example, horse spleen Ft contains about 
90% L- and 10% H- subunits. In bacteria, plants and invertebrates, ferritins are 
exclusively composed of H-like subunits. 
To load apoferritin (apoFt), a Ft molecule that does not contain Fe, requires FeII 
and not, FeIII as the substrate. In broad terms, it is accepted that FeII moves 
through the hydrophilic channels until it finds the ferroxidase center of an H-
subunit, here it is catalytically oxidized to FeIII by reaction with cellular O2. It 
then moves to the cavity where it is finally stored as a ferrihydrite 
nanoparticle.[6] The mechanism of the ferroxidase oxidation of FeII to FeIII, as well 
as the path of FeIII from the ferroxidase center to the cavity, are currently a point 
of controversy.[2,6-10] In any case, if any FeIII remains at the ferroxidase center, 
somehow close to the surface of ferritin, some biomolecules could be able to 
scavenge it. In fact, Hagen et al. have shown that transferrin, a large protein (80 
kDa) that is unable to enter the Ft cavity, scavenges the two FeIII ions of the 
ferroxidase center.[10] However, in these experiments transferrin just served as 
an FeIII sensor to confirm the nature of the ferroxidase center and the results 
have little biological relevance because Ft is basically intracellular, whereas 
transferrin is the plasma FeIII transport protein. 





into the biological consequences of ferroxidase center function, and (b) 
correlating the apoferritin composition resulting FeIII unavailable, we decided to 
study how FeII is oxidized by two apoFts with different H/L ratios: recombinant 
human H-apoFt (HuFtH), a homopolymer of 24 identical H- subunits each with a 
ferroxidase center, and the commonly studied horse spleen apoFt (HsFt), a 
heteropolymer formed of approximately 3 H- and 21 L-subunits (L-subunits lack 
the ferroxidase center). The FeII to FeIII oxidation activities of HuFtH and HsFt, and 
their capacities to make the formed FeIII unavailable, were studied by following a 
very simple protocol. This was based on monitoring the decrease of available 
FeII, and the increase of available FeIII, in a batch of 15 fresh samples initially 
containing FeII and the respective apoFts in catalytic proportions (approx. 200 
FeII/apoFt). The addition, at different reaction times, of an excess of ferrozine (fz) 
or apolactoferrin (Lf) serves as an indicator, via measurement of the respective 
UV-vis absorbances at 562 nm ([FeII(fz)3]2+) or 464 nm (FeIII-Lf), of the 
concentration of available FeII or FeIII at every step of the Ft reconstitution 
process. The combination of FeII decrease and FeIII increase availability patterns 
provides a dynamic picture of the overall Fe uptake process carried out by Ft. 
Hence, monitoring ([FeII(fz)3]2+) concentration, i.e., recording the time 
dependence of A562nm allows evaluation of the capability of each apoFt to oxidize 
FeII because the faster is the FeII oxidation process, the faster is the decrease of 
the UV-vis absorbance at 562 nm. As shown in Figure 1, the free FeII 
concentration decreases in the presence of HsFt (L-rich) to reach a plateau 
corresponding to a remaining 40% of the initial FeII, while the decrease of free 
FeII in the presence of HuFtH (entirely H-subunits) is significantly higher, so that 
within a few minutes almost all the initial FeII is no longer available to react 
with fz. These results corroborate the idea that the ferroxidase activity of apoFt 







                   
Figure 1. Fe(II) availability in the presence of two different apoFts: Absorbance at 
562 nm, i.e. [FeII(fz)3]2+ concentration, after addition, at different times, of ferrozine 
to the mixtures HsFt + FeII (orange) and HuFtH + FeII (yellow). Green data 
correspond to the control (absence of protein). As shown in the control, under our 
experimental conditions, FeII remains stable in solution at least 300 minutes. 
 
An analogous batch of experiments was performed but Lf in the presence of 
bicarbonate was added instead of fz, (see Experimental). Monitoring the UV-vis 
absorbance of the FeIII-Lf complex at 464 nm provides information about the 
concentration of available FeIII produced by the Ft reconstitution process. As can 
be seen in Figure 2, HsFt does not yield any peaks at this wavelength, suggestive 
of the low availability of FeIII formed by this apoFt, whereas HuFtH gives rise to 
the development of the UV-vis band at 464 nm typical of FeIII-Lf, and which is 
independent of the allowed FeII-HuFtH reaction time. This absorbance correlates 
with a permanent concentration of 0.16 mM of free FeIII, which corresponds to 
almost 50% of the FeII that was allowed to react with HuFtH. 
According to previous reports on this subject, we cannot rule out the possibility of 
a small fraction of the initial FeII being stabilized in the ferritin cavity and 





A464nm due to the formation of FeIII -Lf in the presence of HuFtH confirms that for 
this protein, FeII is not available for fz complexation because a large proportion of 
the initial FeII is actually oxidized to FeIII rather than stabilized within the protein 
as FeII. In either case, the presence or absence of a small fraction of stabilized FeII 
within the ferritin cavity is neither the focus of this work nor is it crucial for the 
conclusions which wewill draw, our focus is on the presence/absence of 
available FeIII during the Ft mineralization process. In this context, our results 
clearly demonstrate that once FeII is oxidized by HsFt, the resulting FeIII is in an 
inaccessible form, probably because these FeIII ions are stored inside the protein 
cavity and Lf is too large to pass through the Ft channels to bind FeIII. However, 
although HuFtH oxidizes practically all of the initial FeII, half of the formed FeIII 
is available to large biomolecules such as Lf. Furthermore, according to our 
results and contrasting them with those reported by Hagen et al.,[10] the amount 
of FeIII complexed by Lf during the Fe reconstitution process of HuFtH is almost 
double than that corresponding to the number of Fe atoms at the ferroxidase 
centers (24 x 2 per protein). Here, the protein is present in catalytic quantities, 
and therefore a large excess of FeII has been added (a situation that is probably 
closer to the actual in vivo scenario) and so we can conclude that the target of 
Lf is probably not only the FeIII ions fixed at the ferroxidase centers but also the 
FeIII cations formed at such centers and which are not really stored by HuFtH 
within the protein cavity. This protein, therefore, conclusively exhibits high 
ferroxidase activity but a low Fe storage capacity. 
 
 






Figure 2. FeIII availability after oxidation of FeII by two different apoFt proteins: 
UV-vis spectra after addition, at different times, of lactoferrin to the mixtures 
HuFtH + FeII (left) and HsFt + FeII (right). The inset corresponds to the time 
dependence of the absorbance at 464 nm, i.e. [FeIII-Lf] concentration. 
 
In contrast, HsFt exhibits low ferroxidase activity but with a high FeIII storage 
capacity since we did not observe Fe with Lf, thus indicating that although 
relatively little FeIII is formed, it is genuinely stored within the ferritin cavity (i.e., it 
is not available for a chelating agent). More interestingly, and in a second stage of 
this work, we focused on the biological relevance of our results by investigating 
some of the chemical consequences of the observed FeIII availability during 
reconstitution of Ft. We tried to go one step further beyond the demonstration that 
once FeII has been oxidized at the ferroxidase center of Ft, some FeIII ions can then 
be scavenged by an FeIII chelator. If, according to the present results and those of 
Hagen et al.,[10] FeIII produced in the Ft ferroxidase center is available for 
complexation by a large molecule such as transferrin, it should also be able to act 
as an oxidant against metallothioneins (MTs).[12] This possibility takes special 
relevance in view of the Fenton reactivity of CuI/II ions and the widely assumed 
presence of Cu-containing MTs in brain cells. Bearing this in mind, we studied 
the Fe reconstitution of the two different ferritins from our study (HuFtH and 
HsFt) in the presence of the Cu-loaded forms of two mammalian MT isoforms 
(MT2 and MT3). MTs are small (6 - 10 kDa) and cysteine rich (33%) 
metaloproteins. They are naturally found bound to either ZnII and/or CuI but 





major players in the homeostasis of physiological Zn and Cu.[13,14] We paid 
particular attention to MT2 and MT3 because the former is predominantly 
synthesized in astrocytes and microglia, where ferritin is mainly found in the L-
rich form, while the latter is a brain-specific isoform constitutively expressed in 
neurons, where H-rich ferritins are predominant.[15,16] Therefore, the 
coexistence of certain combinations of Ft and MT (i.e., MT2 with L-rich or MT3 
with H-rich ferritins) can be considered to be a direct reflection of the situation 
encountered in different types of brain cells. In accordance with the Zn-thionein 
character of MT2[17] and the partial Cu-thionein character of MT3,[18,19] they 
would constitute mixed Zn, Cu-MT complexes (instead of homonuclear Cu-MT 
species) when synthesized in the brain, even in the presence of physiologically 
high Cu concentrations. For this reason we used the metal-MT2 and metal-MT3 
preparations that result from the recombinant synthesis of MT2 and MT3 in Cu- 
supplemented E. coli cultures grown under regular aeration,[20] which is the 
closest approximation to mammalian cell conditions. They yielded a mixture of 
Zn1Cu10- and Zn2Cu10- as major species for MT2
[17] and a mixture of Zn4Cu6- and 
Cu10- complexes for MT3[18], which from now on and for the sake of simplicity 
we shall refer to as the Cu-MT2 and Cu-MT3 complexes. 
For these experiments, we prepared a batch of FeII-apoFt mixtures with HsFt and 
with HuFtH, and allowed them to react aerobically for 15 minutes. These 
reaction mixtures were then degassed and saturated with argon prior to the 
addition of the Cu-loaded forms of MT2 or MT3 with the appropriate chelating 
agent, either BTA or fz. The CuI released or the FeII formed as a result of the 
oxidation of the Cu-MTs by FeII could be respectively determined by monitoring 
the UV-vis absorbance at either 480 nm (CuI-BTA) or 562 nm ([FeII(fz)3]2+) with 









Figure 3. UV-vis spectra recorded at different times after the addition of Cu- MT2 + 
BTA (left) and Cu-MT2 + fz (right) to a mixture of HuFtH + FeII. Insets correspond to 
the time dependence of the absorbance at 480 nm (left) and 562 nm (right). 
 
Based on the initial Cu concentration of the Cu-MT2 sample (41 µM), it can be 
concluded that almost 90% of Cu was removed from MT2 after 30 min of 
reaction (35,7 µM final concentration of CuI-BTA). The same reaction with Cu-
MT3 released only 6% of the initially coordinated CuI. However, the parallel 
study of HsFt is dramatically different; no absorbance peak developed at 480 
nm, highlighting the absence of free CuI since, in agreement with the high Fe 
storage capacity of HsFt, there is a very low availability of FeIII in the medium 
to oxidize either Cu-MT2 or Cu-MT3. 
It is therefore reasonable to assume that the FeIII formed after oxidation at the 
HuFtH ferroxidase center is the agent responsible for oxidizing Cu-MT2 on the 
basis of three different experiments: (i) The mixtures of HuFtH, Cu-MT2/Cu-
MT3 and BTA do not exhibit any significant UV-vis absorption corresponding to 
CuI-BTA in the absence of FeII. This points out that, in the absence of FeII, neither 
MT2 nor MT3 are oxidized. (ii) Addition of an FeIII salt, in the same 
concentration as that generated in the FeII + HuFtH experiment, to an anaerobic 
Cu-MT2 solution, but not in one containing Cu-MT3, in the presence of BTA 
produces CuI-BTA with a CuI delivery pattern similar to that of the FeII + HuFtH + 
Cu-MT2 experiment (see Experimental). This clearly indicates that FeIII is a 
powerful oxidant capable of oxidizing the mammalian MT2 isoform in its Cu 
loaded form, while that of MT3 practically resists this oxidizing environment. (iii) 





oxidation is almost complete, Figure 1) Cu-MT2 -together with fz- is added to the 
reaction mixture, the ([FeII(fz)3]2+) complex forms and its concentration increases 
with time (Figure 3). This final experiment evidences that after the reduction of 
the FeII concentration to almost zero during the Fe reconstitution process of 
HuFtH, reaction upon addition of Cu-MT2 again raises the FeII concentration to 
59% of the initial value as a consequence of the oxidation of MT2 by FeIII. 
In summary, in this paper we demonstrate that part of the FeIII formed at the 
ferroxidase centers of HuFtH is available, not only for complexation with an FeIII 
chelator, but also to oxidize Cu-loaded MT2, giving rise to the concomitant 
release of two toxic metals ions, CuI and FeII. The latter reaction does not take 
place when the apoferritin is a H/L heteropolymer such as HsFt. In this case, all 
the FeIII formed at the ferroxidase center is unavailable for either Lf 
complexation or MT oxidation. The chemical scenario we have created is 
especially significant in the brain, where incorrect Fe uptake by Ft has been 
suggested to result in the progression of neurological diseases. Hence, Dobson 
and co-workers proposed that patients with Alzheimer's disease could have a 
dysfunction in brain Fe storage due to a disruption in the balance of ferritin H- 
and L- subunit synthesis.[21] In this sense, our results point out that in cells where 
Cu-MT2 and Ft coexist, there is no danger if the ferritin is L-rich, as it occurs in 
astrocytes and microglia,[16] and both proteins would preserve their integrity and 
functionality. However, if this imbalance in L- and H-subunit synthesis leads to the 
synthesis of pure H apoferritins, and therefore to some events analogous to those 
we have described here in which the high ferroxidase activity and low Fe 
storage capacity of a H-rich Ft would provoke CuI liberation from Cu-MT2, then 
the presence of two free and toxic metals such as CuI and FeII, could produce 
fatal results for the cell. Interestingly, Cu-MT3 does not react with either HuFtH 
or HsFt in the presence of FeII thus making the Cu-MT3 and Ft pair a non-
deleterious combination in neurons. This is extremely relevant because in neuron 
cells Ft is mainly present in H-rich forms,[16] which would lead to a harmful 
interaction should the predominant MT isoform present be that of MT2. What we 
wish to underline here is that the process of Fe storage in ferritin affects parallel 
metal metabolisms depending on the protein shell itself. Following on from that 





results in a significant decrease in the amount of Fe stored, meaning that there is 
free FeIII available that is capable of oxidizing Cu-MT2, ultimately leading to the 
liberation of toxic FeII and CuI. As a final conclusion, it is worth highlighting that 
the current results reconcile the simultaneous presence of ferritins and MT in 
cells,[12] provided that the correct combination of isoforms is preserved, 
otherwise metal-related neuronal disorders could be triggered if parting from 
this ideal combination. 
 
Experimental Section 
Materials. Horse spleen apoFt (HsFt) was obtained from Sigma and was 
exhaustively dialyzed against Milli-Q water using a Spectra/Por Float-A-Lyzer 
with a molecular weight cut off (MWCO) of 300,000 Da. Recombinant human H-Ft 
(HuFtH) was prepared as previously described[21,22] and rendered iron free by 
dialysis against sodium hydrosulfite (dithionite), Na2S2O4, and complexation with 
2,2’-bipyridyl at pH 6.0[23], to isolate an apoferritin containing 10 Fe/protein. The 
Cu loaded forms of the mammalian metallothionein isoforms MT2 and MT3 were 
recombinantly synthesized and characterized (ICP-AES and ESI-MS) as previously 
reported.[17,18] The final preparations were 0.13 x 10-4 M (MT2) and 0.35 x 10-4 
M (MT3) in 50 mM Tris-HCl, pH 7.5 buffer, and they were deaerated under N2 flux 
to avoid the presence of O2 during the described reactions. Monoferric lactoferrin 
was purchased from Fonterra. Lf was prepared following the same protocol as 
reported previously.[24]  
Measurement of available FeII. Batches of 15 fresh solutions for each type of 
apoferritin, 0.2 µM in 0.15 M HEPES buffer, pH 7.0, and fresh aqueous solutions 
of Fe(SO4)2(NH4)·6H2O (final Fe 0.0353 mM) were mixed. 1 mL of an aqueous 
ferrozine solution (3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p-disulfonic acid 
monosodium salt hydrate, Aldrich), final concentration 0.935 mM, was added to 
every sample after 1, 2, 3, 4, 5, 8,10, 15, 20, 30, 60, 100, 200 and 300 min and 
the UV-visible spectra immediately recorded. Available FeII concentration was 
calculated for every sample in the batch from the UV-vis absorbance measured at 






Measurement of available FeIII. A batch of four fresh solutions of each apoferritin, 
0.2 µM in 0.15 M HEPES buffer containing 10 mM of NaHCO3, pH 7.0, and fresh 
aqueous solutions of Fe(SO4)2(NH4)·6H2O (final Fe 0.353 mM) were mixed. 200 
µL of an aqueous solution of Lf (final concentration 200 μM) was added to every 
sample after 5, 10, 20 and 60 min and the UV-vis spectra recorded. Available FeIII 
concentration was calculated for every sample of the batch from the UV-vis 
absorbance measured at 464 nm, due to formation of the [FeIII(Lf)] complex (ε = 
2,600 M-1cm-1). 
Measurement of CuI during ferritin reconstitution in the presence of Cu-MT. In a 
parallel experiment, HuFtH and HsFt (0.2 µM) in 0.15 M HEPES buffer, pH 7.0, 
were incubated with aqueous solutions of Fe(SO4)2(NH4)·6H2O (final [Fe] 0.035 
mM) at 37 ºC and in aerobic conditions for 15 min. The reaction mixture was then 
totally deoxygenated under nitrogen flux and kept under an anaerobic 
atmosphere prior to the addition of Cu-MT2 (100 µL, 5.2 µM, [Cu] 41 µM) or Cu-
MT3 (100 µL, 4.7 µM, 40 µM). Then, 10 µL of 0.4 mM BTA 
(bathocuproinedisulfonic acid disodium salt) was added to the mixture in order to 
detect CuI by observation of the UV-vis band at 480 nm due to formation of the 
[CuI(BTA)2]+ complex (ε = 14,000 M-1cm-1). The same experiments carried out in 
the absence of FeII did not produce an absorbance peak at 480 nm for the UV-vis 
spectra of [CuI(BTA)2]+.  
Measurement of FeIII reduction to FeII during HuFtH ferritin reconstitution in the 
presence of Cu-MT2. The previous protocol was followed but using ferrozine 
instead of BTA as a chelating agent for the purposes of measuring the FeII 
concentration. We noted that after 15 min of FeII reconstitution by HuFtH, the 
FeII concentration had dramatically decreased (Figure 1). Therefore the increase 
of FeII concentration in this experiment corresponds to the oxidation of Cu-MT2 
by FeIII with the subsequent formation of FeII, which is ultimately detected and 
quantified by its complexation with fz. 
Oxidation of Cu-MT by FeIII. In a parallel experiment, Cu-MT2 (100 µL, 3 µM) and 
Cu-MT3 (100 µL, 3 µM) were incubated at 37 ºC in a degassed aqueous solution of 
FeIII acetate (0.02 mM) under Ar. BTA or fz was added to detect and quantify the 
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